News & Events

News

All categories

Earnings

Press Release

All years

2019

2018

2017

2016

2015

2014

Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress

November 19, 2019

Affimed to Present at the Jefferies 2019 London Healthcare Conference

November 14, 2019

Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019

November 14, 2019

Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares

November 13, 2019

Affimed Announces Pricing of Public Offering of Common Shares

November 8, 2019

Affimed Announces Proposed Public Offering of Common Shares

November 7, 2019

Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

November 7, 2019

Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

November 7, 2019

Affimed Reports Progress on Key Clinical Development Programs

October 15, 2019

Affimed to Participate in Investor Conferences in September

August 28, 2019

Events

All

Scientific

Investors

20Nov

Jefferies 2019 London Healthcare Conference

November 20 - 21, 2019 (London, UK)
Presenter: Adi Hoess

09Dec

Antibody Engineering & Therapeutics

December 9 - 13, 2019 (San Diego, USA)
Presenter: Michael Tesar

Webcasts
More events

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.